IL93424A - Dual-activity pharmacy tablet - Google Patents

Dual-activity pharmacy tablet

Info

Publication number: IL93424A
Authority: IL; Israel
Prior art keywords: tablet; dose; active ingredient; level; dual
Prior art date: 1989-02-21

Application number

IL9342490A

Other languages

English (en)

Hebrew (he)

Other versions

IL93424A0 (en

Original Assignee

Norwich Eaton Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-21

Filing date

1990-02-16

Publication date

1994-02-27

1990-02-16 Application filed by Norwich Eaton Pharma filed Critical Norwich Eaton Pharma

1990-11-29 Publication of IL93424A0 publication Critical patent/IL93424A0/xx

1994-02-27 Publication of IL93424A publication Critical patent/IL93424A/en

Links

230000009977 dual effect Effects 0.000 title claims abstract description 20
239000004480 active ingredient Substances 0.000 claims abstract description 61
239000011159 matrix material Substances 0.000 claims abstract description 21
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims abstract description 18
229960002146 guaifenesin Drugs 0.000 claims abstract description 18
239000007916 tablet composition Substances 0.000 claims abstract description 18
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 13
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
239000000203 mixture Substances 0.000 claims description 47
239000000314 lubricant Substances 0.000 claims description 11
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
239000007884 disintegrant Substances 0.000 claims description 9
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 7
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 7
229960000395 phenylpropanolamine Drugs 0.000 claims description 7
239000002861 polymer material Substances 0.000 claims description 6
239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
229920000642 polymer Polymers 0.000 claims description 5
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
241000416162 Astragalus gummifer Species 0.000 claims description 3
229920002907 Guar gum Polymers 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 3
229920001615 Tragacanth Polymers 0.000 claims description 3
229920003086 cellulose ether Polymers 0.000 claims description 3
229960000913 crospovidone Drugs 0.000 claims description 3
235000010417 guar gum Nutrition 0.000 claims description 3
239000000665 guar gum Substances 0.000 claims description 3
229960002154 guar gum Drugs 0.000 claims description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
239000008109 sodium starch glycolate Substances 0.000 claims description 3
229920003109 sodium starch glycolate Polymers 0.000 claims description 3
229940079832 sodium starch glycolate Drugs 0.000 claims description 3
229940032147 starch Drugs 0.000 claims description 3
239000008107 starch Substances 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
229920001285 xanthan gum Polymers 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
229920000569 Gum karaya Polymers 0.000 claims description 2
235000010980 cellulose Nutrition 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
229960001681 croscarmellose sodium Drugs 0.000 claims description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
239000003456 ion exchange resin Substances 0.000 claims description 2
229920003303 ion-exchange polymer Polymers 0.000 claims description 2
235000010494 karaya gum Nutrition 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
235000010493 xanthan gum Nutrition 0.000 claims description 2
239000000230 xanthan gum Substances 0.000 claims description 2
229940082509 xanthan gum Drugs 0.000 claims description 2
-1 hydroxypropyl methyl Chemical group 0.000 claims 2
229940106135 cellulose Drugs 0.000 claims 1
150000004676 glycans Chemical class 0.000 claims 1
239000013081 microcrystal Substances 0.000 claims 1
238000010521 absorption reaction Methods 0.000 abstract description 3
230000003247 decreasing effect Effects 0.000 abstract description 2
238000013270 controlled release Methods 0.000 abstract 1
210000003750 lower gastrointestinal tract Anatomy 0.000 abstract 1
239000003826 tablet Substances 0.000 description 91
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
239000004615 ingredient Substances 0.000 description 10
238000000034 method Methods 0.000 description 9
239000003814 drug Substances 0.000 description 8
238000013268 sustained release Methods 0.000 description 8
239000012730 sustained-release form Substances 0.000 description 8
239000002552 dosage form Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
230000003111 delayed effect Effects 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
239000000463 material Substances 0.000 description 6
239000000454 talc Substances 0.000 description 6
229910052623 talc Inorganic materials 0.000 description 6
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 6
235000021355 Stearic acid Nutrition 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
239000008117 stearic acid Substances 0.000 description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000000945 filler Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000011149 active material Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
239000008116 calcium stearate Substances 0.000 description 3
235000013539 calcium stearate Nutrition 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000007950 delayed release tablet Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
239000012530 fluid Substances 0.000 description 3
229940049654 glyceryl behenate Drugs 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 3
229960000244 procainamide Drugs 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
229940045902 sodium stearyl fumarate Drugs 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000007939 sustained release tablet Substances 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
239000005862 Whey Substances 0.000 description 2
102000007544 Whey Proteins Human genes 0.000 description 2
108010046377 Whey Proteins Proteins 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
235000011132 calcium sulphate Nutrition 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
235000019700 dicalcium phosphate Nutrition 0.000 description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
229940046813 glyceryl palmitostearate Drugs 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
229940042472 mineral oil Drugs 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000049 pigment Substances 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
229960003885 sodium benzoate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
229940033134 talc Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
229960002213 alprenolol Drugs 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
238000011369 optimal treatment Methods 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
229960000436 phendimetrazine Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229960002816 potassium chloride Drugs 0.000 description 1
229940070017 potassium supplement Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
229960002454 quinidine gluconate Drugs 0.000 description 1
229960004482 quinidine sulfate Drugs 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
229960004016 sucrose syrup Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL9342490A 1989-02-21 1990-02-16 Dual-activity pharmacy tablet IL93424A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/314,672 US5032406A (en)	1989-02-21	1989-02-21	Dual-action tablet

Publications (2)

Publication Number	Publication Date
IL93424A0 IL93424A0 (en)	1990-11-29
IL93424A true IL93424A (en)	1994-02-27

Family

ID=23220946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9342490A IL93424A (en)	1989-02-21	1990-02-16	Dual-activity pharmacy tablet

Country Status (15)

Country	Link
US (1)	US5032406A (de)
EP (1)	EP0384514B1 (de)
JP (1)	JP2895146B2 (de)
KR (1)	KR0173115B1 (de)
AT (1)	ATE97571T1 (de)
AU (1)	AU632793B2 (de)
CA (1)	CA2010037C (de)
DE (1)	DE69004708T2 (de)
DK (1)	DK0384514T3 (de)
ES (1)	ES2060923T3 (de)
IE (1)	IE63311B1 (de)
IL (1)	IL93424A (de)
NZ (1)	NZ232604A (de)
PH (1)	PH27331A (de)
ZA (1)	ZA901261B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681583A (en) *	1993-07-09	1997-10-28	Apr Applied Pharma Research Sa	Multilayered controlled-release oral solid pharmaceutical forms

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5200197A (en) *	1989-11-16	1993-04-06	Alza Corporation	Contraceptive pill
IE64128B1 (en) *	1990-02-26	1995-07-12	Byrne Rynne Holdings Ltd	A pharmaceutical composition
US5284659A (en) *	1990-03-30	1994-02-08	Cherukuri Subraman R	Encapsulated flavor with bioadhesive character in pressed mints and confections
US5158728A (en) *	1991-04-12	1992-10-27	Elizabeth-Hata International, Inc.	Multi-layer medicinal tablet forming machine and method for using the same
FI93924C (fi) *	1991-09-17	1995-06-26	Martti Lauri Antero Marvola	Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
DE69222006T2 (de) *	1991-10-30	1998-01-22	Glaxo Group Ltd	Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
DE69224809T2 (de) *	1991-12-30	1998-07-09	Akzo Nobel Nv	Thyroaktive Zusammensetzung mit kontrollierter Freigabe
WO1993019741A1 (en) *	1992-03-31	1993-10-14	Benzon Pharma A/S	A pharmaceutical formulation
US5656296A (en) *	1992-04-29	1997-08-12	Warner-Lambert Company	Dual control sustained release drug delivery systems and methods for preparing same
IT1260505B (it) †	1992-06-01	1996-04-09	Poli Ind Chimica Spa	Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5422122A (en) *	1992-08-04	1995-06-06	Eurand America, Incorporated	Controlled release potassium chloride tablet
US6080428A (en)	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en)	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en)	1993-09-20	2004-06-08	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en)	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en)	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5399358A (en) *	1993-11-12	1995-03-21	Edward Mendell Co., Inc.	Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) *	1994-03-04	1995-03-21	Edward Mendell Co., Inc.	Controlled release oxybutynin formulations
US5399362A (en) *	1994-04-25	1995-03-21	Edward Mendell Co., Inc.	Once-a-day metoprolol oral dosage form
US5595759A (en) *	1994-11-10	1997-01-21	Alza Corporation	Process for providing therapeutic composition
EP0823255A4 (de) *	1995-04-03	1999-01-27	Chugai Pharmaceutical Co Ltd	Sucralfat enthaltendes arzneimittel
US5759574A (en) *	1995-05-15	1998-06-02	Bothe; Steven T.	Tel-tale-tablets
IT1276689B1 (it) *	1995-06-09	1997-11-03	Applied Pharma Res	Forma farmaceutica solida ad uso orale
US5807579A (en) *	1995-11-16	1998-09-15	F.H. Faulding & Co. Limited	Pseudoephedrine combination pharmaceutical compositions
AU2068797A (en) *	1996-01-29	1997-08-20	Edward Mendell Co. Inc.	Sustained release excipient
KR19980077329A (ko) *	1997-04-18	1998-11-16	이범진	이중층 약물 함유 제어방출성 제제
US6143309A (en) *	1998-03-12	2000-11-07	Archimica (Florida), Inc.	Delivery of hydroxy carboxylic acids
US6372254B1 (en) *	1998-04-02	2002-04-16	Impax Pharmaceuticals Inc.	Press coated, pulsatile drug delivery system suitable for oral administration
US6387381B2 (en)	1998-09-24	2002-05-14	Ez-Med Company	Semi-moist oral delivery system
US6773716B2 (en) *	1999-04-06	2004-08-10	Wm. Wrigley Jr. Company	Over-coated chewing gum formulations
IT1313590B1 (it) *	1999-08-03	2002-09-09	Formenti Farmaceutici Spa	Composizioni a rilascio controllato di acido acetilsalicilico.
AR030557A1 (es)	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6955821B2 (en) *	2000-04-28	2005-10-18	Adams Laboratories, Inc.	Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) *	2000-04-28	2011-09-06	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
US7838032B2 (en) *	2000-04-28	2010-11-23	Reckitt Benckiser Inc.	Sustained release of guaifenesin
US7985420B2 (en) *	2000-04-28	2011-07-26	Reckitt Benckiser Inc.	Sustained release of guaifenesin combination drugs
US6372252B1 (en) *	2000-04-28	2002-04-16	Adams Laboratories, Inc.	Guaifenesin sustained release formulation and tablets
DE10031043A1 (de) *	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
NZ527832A (en) *	2001-03-13	2006-03-31	Penwest Pharmaceuticals Co	Chronotherapeutic dosage forms
JP2002326961A (ja) *	2001-04-27	2002-11-15	Taiyo Kagaku Co Ltd	打錠用滑沢剤
US20030012820A1 (en) *	2001-06-12	2003-01-16	Upadhyay Ajay Hasmukhlal	Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
US6837696B2 (en) *	2001-09-28	2005-01-04	Mcneil-Ppc, Inc.	Apparatus for manufacturing dosage forms
CA2461616A1 (en) *	2001-09-28	2003-04-03	Mcneil-Ppc, Inc.	Composite dosage forms having an inlaid portion
CA2481091A1 (en) *	2002-04-05	2003-10-23	Penwest Pharmaceuticals Co.	Sustained release metoprolol formulations
EA007156B1 (ru) *	2002-04-15	2006-08-25	Адамс Лэборетриз, Инк.	Замедленно высвобождающие лекарственные композиции гвайфенезина
DE10224108A1 (de) *	2002-05-29	2004-01-29	Grünenthal GmbH	1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
US7632521B2 (en) *	2003-07-15	2009-12-15	Eurand, Inc.	Controlled release potassium chloride tablets
EA200600598A1 (ru) *	2003-09-19	2006-08-25	Пенвест Фармасьютикалз Ко.	Лекарственные формы замедленного высвобождения
AU2004273958A1 (en) *	2003-09-19	2005-03-31	Penwest Pharmaceuticals Co.	Chronotherapeutic dosage forms
MY147202A (en) *	2003-11-26	2012-11-14	Novartis Ag	Compositions comprising organic compounds
CN1327838C (zh) *	2004-07-08	2007-07-25	北京科信必成医药科技发展有限公司	维生素c口腔崩解片及其制备方法
CN1297263C (zh) *	2004-10-25	2007-01-31	北京科信必成医药科技发展有限公司	葡萄糖酸钙口腔崩解片及其制备工艺
US8673352B2 (en)	2005-04-15	2014-03-18	Mcneil-Ppc, Inc.	Modified release dosage form
US20060257473A1 (en) *	2005-05-11	2006-11-16	Porranee Puranajoti	Extended release tablet
US8765178B2 (en)	2006-07-19	2014-07-01	Watson Laboratories, Inc.	Controlled release formulations and associated methods
US20090202633A1 (en) *	2008-01-03	2009-08-13	Siva Ramakrishna Velaga	Extended release formulations of guaifenesin
WO2010028290A1 (en) *	2008-09-04	2010-03-11	Farnam Companies, Inc.	Chewable sustained release formulations
TR201001903A2 (tr)	2010-03-12	2011-04-21	Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş.	Uzatılmış salımlı tiyokolşiklozit tablet.
GB201506755D0 (en)	2015-04-21	2015-06-03	Reckitt Benckiser Llc	Novel pharmaceutical formulation
CA2902911C (en)	2014-10-31	2017-06-27	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
KR101684797B1 (ko) *	2015-08-27	2016-12-08	오철환	개폐구조를 갖는 글루건
WO2017062997A1 (en)	2015-10-09	2017-04-13	Reckitt Benckiser Llc	Pharmaceutical formulation
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
CN112472679A (zh) *	2020-12-02	2021-03-12	上海汉维生物医药科技有限公司	双释放片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE556141A (de) *	1956-03-27
US2951792A (en) *	1959-11-18	1960-09-06	Smith Kline French Lab	Sustained release pharmaceutical tablets
US3388041A (en) *	1964-01-27	1968-06-11	Richardson Merrell Inc	High dosage sustained release tablet
FR1545612A (fr) *	1967-06-15	1968-11-15	Dausse Lab	Procédé de fabrication de comprimés
GB1276089A (en) *	1968-08-23	1972-06-01	Pfizer Ltd	Pharmaceutical preparations
US3558768A (en) *	1969-12-19	1971-01-26	Sterling Drug Inc	Sustained release pharmaceutical compositions
SE418247B (sv) *	1975-11-17	1981-05-18	Haessle Ab	Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
DE3113901A1 (de) *	1981-04-07	1982-10-28	Basf Ag, 6700 Ludwigshafen	Wirkstoffzubereitung zur oralen applikation
US4552899A (en) *	1984-04-09	1985-11-12	Analgesic Associates	Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IT1191674B (it) *	1986-03-07	1988-03-23	Eurand Spa	Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4756911A (en) *	1986-04-16	1988-07-12	E. R. Squibb & Sons, Inc.	Controlled release formulation
DE3720757A1 (de) *	1987-06-24	1989-01-05	Bayer Ag	Dhp-manteltablette

1989
- 1989-02-21 US US07/314,672 patent/US5032406A/en not_active Expired - Fee Related
1990
- 1990-02-12 ES ES90200313T patent/ES2060923T3/es not_active Expired - Lifetime
- 1990-02-12 EP EP90200313A patent/EP0384514B1/de not_active Expired - Lifetime
- 1990-02-12 DK DK90200313.6T patent/DK0384514T3/da active
- 1990-02-12 AT AT90200313T patent/ATE97571T1/de not_active IP Right Cessation
- 1990-02-12 DE DE90200313T patent/DE69004708T2/de not_active Expired - Fee Related
- 1990-02-14 CA CA002010037A patent/CA2010037C/en not_active Expired - Fee Related
- 1990-02-16 IL IL9342490A patent/IL93424A/en not_active IP Right Cessation
- 1990-02-19 KR KR1019900001989A patent/KR0173115B1/ko not_active Expired - Fee Related
- 1990-02-19 PH PH40068A patent/PH27331A/en unknown
- 1990-02-20 AU AU49970/90A patent/AU632793B2/en not_active Ceased
- 1990-02-20 JP JP2039556A patent/JP2895146B2/ja not_active Expired - Lifetime
- 1990-02-20 NZ NZ232604A patent/NZ232604A/xx unknown
- 1990-02-20 ZA ZA901261A patent/ZA901261B/xx unknown
- 1990-02-21 IE IE62990A patent/IE63311B1/en not_active IP Right Cessation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681583A (en) *	1993-07-09	1997-10-28	Apr Applied Pharma Research Sa	Multilayered controlled-release oral solid pharmaceutical forms

Also Published As

Publication number	Publication date
IE63311B1 (en)	1995-04-05
CA2010037C (en)	1995-10-31
NZ232604A (en)	1992-10-28
KR0173115B1 (ko)	1999-02-01
ZA901261B (en)	1990-11-28
DE69004708D1 (de)	1994-01-05
IE900629L (en)	1990-08-21
JPH03200724A (ja)	1991-09-02
DE69004708T2 (de)	1994-03-24
PH27331A (en)	1993-06-08
AU632793B2 (en)	1993-01-14
IL93424A0 (en)	1990-11-29
KR900012606A (ko)	1990-09-01
JP2895146B2 (ja)	1999-05-24
US5032406A (en)	1991-07-16
ES2060923T3 (es)	1994-12-01
EP0384514A3 (de)	1991-04-03
CA2010037A1 (en)	1990-08-21
ATE97571T1 (de)	1993-12-15
AU4997090A (en)	1990-08-30
EP0384514B1 (de)	1993-11-24
DK0384514T3 (da)	1994-02-07
EP0384514A2 (de)	1990-08-29

Legal Events

Date	Code	Title
1996-05-14	KB	Patent renewed
2000-08-31	KB	Patent renewed
2004-11-10	RH1	Patent not in force

Publication	Publication Date	Title
CA2010037C (en)	1995-10-31	Dual-action tablet
JP5788331B2 (ja)	2015-09-30	浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤
US20110071137A1 (en)	2011-03-24	Process for preparing sustained release tablets
US20030203878A1 (en)	2003-10-30	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CA2182004C (en)	2000-10-31	Film coated tablet of paracetamol and domperidone
JP5420590B2 (ja)	2014-02-19	ｐＨ非依存延長放出性医薬組成物
CZ298851B6 (cs)	2008-02-27	Tableta pro rízené podávání úcinných látek
KR101272470B1 (ko)	2013-06-14	레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
WO2010026467A2 (en)	2010-03-11	Controlled release dosage form of high solubility active ingredient
EP1496868A1 (de)	2005-01-19	Darreichungsform zur kontrollierten freisetzung von carbidopa und levodopa
EP2010158B1 (de)	2016-02-17	Formulierungen mit kontrollierter freisetzung aus unbeschichteten diskreten einheiten und matrix mit verzögerter freisetzung
EP1589957A1 (de)	2005-11-02	Pharmazeutische zusammensetzungen und herstellungsverfahren dafür
SK286651B6 (sk)	2009-03-05	Perorálna kompozícia s riadeným uvoľňovaním
US20090149543A1 (en)	2009-06-11	Solid pharmaceutical compositions comprising lumiracoxib
EP0381182B1 (de)	1995-08-02	Erosionsgesteuertes Freisetzungssystem für Wirkstoffe sowie Verfahren zu dessen Herstellung

IL93424A - Dual-activity pharmacy tablet - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (2)

Family

ID=23220946

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (64)

Family Cites Families (12)

Cited By (1)

Also Published As

Similar Documents

Legal Events